We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+11.61%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$249M
AUM Growth
-$11.8M
Cap. Flow
-$27.1M
Cap. Flow %
-10.86%
Top 10 Hldgs %
71.1%
Holding
28
New
5
Increased
5
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$12.8M
2
IRON icon
Disc Medicine
IRON
+$12.3M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$11.5M
4
FOLD
Amicus Therapeutics
FOLD
+$8.93M
5
ABVX
Abivax
ABVX
+$8.03M

Top Sells

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$17.7M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$16.2M
3
CYTK icon
Cytokinetics
CYTK
+$14.3M
4
BIIB icon
Biogen
BIIB
+$8.4M
5
ATXS
Astria Therapeutics
ATXS
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRNX icon
1
Crinetics Pharmaceuticals
CRNX
$8.87B
$30.9M 12.39%
660,143
-126,989
-16% -$4.97M
ARGX icon
2
argenx
ARGX
$55.6B
$25.8M 10.35%
65,597
+14,422
+28% +$5.59M
CYTK icon
3
Cytokinetics
CYTK
$10.9B
$18.5M 7.41%
263,701
-184,443
-41% -$14.3M
KALV
4
DELISTED
KalVista Pharmaceuticals
KALV
$17.1M 6.86%
1,441,952
-365,611
-20% -$4.87M
MRUS
5
DELISTED
Merus
MRUS
$17M 6.8%
376,629
-12,704
-3% -$515K
IRON icon
6
Disc Medicine
IRON
$2.85B
$15.9M 6.36%
254,803
+190,019
+293% +$12.3M
ASND icon
7
Ascendis Pharma A/S
ASND
$16.6B
$15.6M 6.27%
103,428
-28,331
-22% -$4.04M
ANAB icon
8
AnaptysBio
ANAB
$1.59B
$13.2M 5.29%
586,031
-78,245
-12% -$1.85M
PCVX icon
9
Vaxcyte
PCVX
$8.01B
$12.6M 5.07%
+185,175
New +$12.8M
COGT icon
10
Cogent Biosciences
COGT
$6.91B
$10.7M 4.3%
1,595,021
+838,340
+111% +$5.18M
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
$10.6M 4.24%
898,381
+698,408
+349% +$8.93M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.6B
$10.4M 4.17%
119,188
– –
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$1.82B
$9.47M 3.8%
397,997
-120,802
-23% -$2.69M
ABVX
14
Abivax
ABVX
$11.2B
$8.91M 3.57%
+622,970
New +$8.03M
IRWD icon
15
Ironwood Pharmaceuticals
IRWD
$644M
$8.23M 3.3%
+944,912
New +$11.5M
PHAT icon
16
Phathom Pharmaceuticals
PHAT
$953M
$5.32M 2.13%
500,987
+340,912
+213% +$2.9M
ITOS
17
DELISTED
iTeos Therapeutics
ITOS
$5.28M 2.12%
387,095
-441,137
-53% -$4.81M
APLS
18
DELISTED
Apellis Pharmaceuticals
APLS
$4.2M 1.68%
71,463
-71,464
-50% -$4.56M
GERN icon
19
Geron
GERN
$949M
$3.71M 1.49%
+1,123,995
New +$2.52M
MORF
20
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$3.01M 1.21%
85,632
-126,711
-60% -$4.25M
CABA icon
21
Cabaletta Bio
CABA
$444M
$2.95M 1.18%
+173,173
New +$3.72M
ALNY icon
22
Alnylam Pharmaceuticals
ALNY
$37.2B
– –
-10,327
Closed -$1.98M
AMLX icon
23
Amylyx Pharmaceuticals
AMLX
$2.17B
– –
-1,099,268
Closed -$16.2M
ATXS
24
DELISTED
Astria Therapeutics
ATXS
– –
-990,663
Closed -$7.61M
BIIB icon
25
Biogen
BIIB
$29.5B
– –
-32,469
Closed -$8.4M
1
2

Similar funds

LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $552M AUM 22.73% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $553M AUM 26.47% 1-Year Est. Return

Saturn V Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Saturn V Capital Management held 28 positions worth $249M, down 4.5% from $261M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Saturn V Capital Management withdrew a net $27.1M in Q1 2024, closing 7 positions and reducing 10 holdings. Its most notable exit was Cymabay Therapeutics, an estimated $17.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Saturn V Capital Management opened a new position in Vaxcyte worth $12.6M.

  • Saturn V Capital Management's largest Q1 2024 buy was Vaxcyte: 185,175 shares worth $12.6M.
  • Saturn V Capital Management added most to Disc Medicine in Q1 2024, an estimated $12.3M increase.
  • Saturn V Capital Management's biggest Q1 2024 reduction was Cytokinetics, cutting an estimated $14.3M.
  • Saturn V Capital Management fully exited Cymabay Therapeutics in Q1 2024, selling an estimated $17.7M.
  • Saturn V Capital Management's ten largest holdings make up 71% of its $249M portfolio in Q1 2024.
  • Saturn V Capital Management opened 5 new positions and closed 7 in Q1 2024.
  • Saturn V Capital Management's portfolio value fell 4.5% quarter-over-quarter to $249M.

Based on Saturn V Capital Management's 13F filing for Q1 2024, filed 15 May 2024.